← Leaderboards
Christopher Holmes Newton-Cheh
Massachusetts General Hospital
$8,878,611
Attributed
$11,675,579
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$11,675,579 · 5
By mechanism
R01$10,879,079 · 4
K23$796,500 · 1
Top collaborators
- Roy H Perlis4 shared
- Thomas J Wang4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Michael A Rosenberg$4,803,435
- Emmanuel S Buys$2,263,086
Others in their field
Top investigators on “Variant”
- Richard A Gibbs · Baylor College Of Medicine$367,607,426
- Richard K. Wilson · Washington University$295,336,569
- Stacey Gabriel · Massachusetts Institute Of Technology$169,231,712
- David Heimbrook · Leidos Biomedical Research, Inc.$125,120,179
- Heidi L Rehm · Broad Institute, Inc.$96,250,516
- Margaret A Pericak-Vance · Doheny Eye Institute$83,999,609
Research focus
VariantGeneticBaseGenetic VariantResponseGenotypeGeneral PopulationResearch PersonnelInvestigationPhenotypeGenesTraitRisk FactorsVariation (Genetics)RestArrhythmiaMassachusettsPharmaceutical PreparationsComplexTorsades De PointesGenome Wide Association StudyInsightDna ResequencingSampling
Grant awards (21)
Influence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug response$681,345
R01 · FY2021 · HL · contact PI
Influence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug response$818,409
R01 · FY2020 · HL · contact PI
Influence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug response$818,355
R01 · FY2019 · HL · contact PI
Influence of genetic variation on QT prolongation over the lifecourse and as a cardiotoxic drug response$711,286
R01 · FY2018 · HL · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$552,229
R01 · FY2018 · HL
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2017 · HL
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2016 · HL
Physiologic Profiling of sGC Genetic Variants$545,145
R01 · FY2016 · HL · contact PI
Genetics of Cardiotoxic Drug Response to Psychiatric Therapy$714,263
R01 · FY2015 · HL
Physiologic Profiling of sGC Genetic Variants$561,737
R01 · FY2015 · HL · contact PI
Physiologic profiling of sGC genetic variants$559,873
R01 · FY2014 · HL · contact PI
Physiologic effects of natriuretic peptide genetic variation$716,806
R01 · FY2013 · HL · contact PI
Physiologic profiling of sGC genetic variants$588,992
R01 · FY2013 · HL · contact PI
Physiologic effects of natriuretic peptide genetic variation$754,786
R01 · FY2012 · HL
Physiologic effects of natriuretic peptide genetic variation$756,716
R01 · FY2011 · HL
Physiologic effects of natriuretic peptide genetic variation$670,611
R01 · FY2010 · HL
Genetic determinants of cardiac repolarization$159,300
K23 · FY2009 · HL · contact PI
Genetic determinants of cardiac repolarization$159,300
K23 · FY2008 · HL · contact PI
Genetic determinants of cardiac repolarization$159,300
K23 · FY2007 · HL · contact PI
Genetic determinants of cardiac repolarization$159,300
K23 · FY2006 · HL · contact PI
Genetic determinants of cardiac repolarization$159,300
K23 · FY2005 · HL